Before investigating the roles of KLF10 and EGFR in PDT reversing cholangiocarcinoma gemcitabine resistance, we first examined the predicted KLF10 binding and negative regulation of EGFR. The gene discussed is EGFR; the disease is cholangiocarcinoma.